JPMorgan lowered the firm’s price target on Ceribell (CBLL) to $17 from $21 and keeps an Overweight rating on the shares. The company reported another good “beat-and-raise” with tailwinds heading into 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc. Receives Buy Rating Due to Strong Financial Performance and Strategic Growth Initiatives
- Ceribell, Inc. Reports Strong Q3 2025 Revenue Growth
- Ceribell, Inc. Receives Buy Rating from Josh Jennings Amid Strong Q3 Performance and Future Growth Potential
- Ceribell, Inc.: Strong Q3 Performance and Promising Growth Prospects Drive Buy Rating
- Ceribell raises FY25 revenue view to $87M-$89M from $85M-$88M